New Search

If you are not happy with the results below please do another search

1271 search results for:

52

EC approves Polpharma Biologics’ Tyruko biosimilar for MS

Polpharma Biologics, an international biotech company focused on developing and manu­facturing biosimilars, has received approval from the European Commission for Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.

60

Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina

Cambrex announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina. This expansion doubles the facility’s manufacturing capacity, with new state-of-the-art analytical and chemical development laboratories, two new clinical manufacturing suites, and a small-scale commercial manufacturing operation with three work centers […]